Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial

Morriss, Richard; Patel, Shireen; Boutry, Clement; Patel, Priya; Guo, Boliang; Briley, Paul M.; Butler, Deborah; Craven, Michael; Duncan, Ashley; Griffiths, Christopher; Higton, Fred; McNaughton, Rebecca; Nixon, Neil; Prasad, Vibhore; Sayal, Kapil; Smart, David; Zafar, Azhar; Kai, Joe

Abstract

Background: Randomised sham-controlled trials of cranial electrostimulation with the Alpha-Stim Anxiety Insomnia and Depression (AID) device have reported improved anxiety and depression symptoms; however, no adequately powered sham-controlled trials in major depression are available. We investigated whether active Alpha-Stim AID is superior to sham Alpha-Stim AID in terms of clinical effectiveness for depression symptoms in major depression. Methods: The Alpha-Stim-D trial was a multicentre, parallel group, double-blind, randomised controlled trial, recruiting participants from 25 primary care centres in two regions in England, UK. Eligible participants were aged 16 years or older with a current diagnosis of primary major depression, a score of 10–19 on the nine-item Patient Health Questionnaire, and had been offered or prescribed and reported taking antidepressant medication for at least 6 weeks in the previous 3 months. Main exclusion criteria were contraindications to Alpha-Stim AID device use, having persistent suicidal ideation or self-harm, neurological conditions, a substance use disorder or dependence, an eating disorder, bipolar disorder, or non-affective psychosis, or receiving psychological treatment in the past 3 months. Eligible participants were randomly assigned (1:1, minimised by region, anxiety disorder, and antidepressant use) to 1 h daily use of active (100 μA) or sham Alpha-Stim AID treatment for 8 weeks. Randomisation was via an independent web-based system, with participants, outcome assessors, and data analyst masked to treatment assignment. The primary outcome was change from baseline in score on the 17-item Hamilton Depression Rating Scale (HDRS-17, GRID version) at 16 weeks after randomisation, with participants analysed by intention to treat (ITT; all randomly assigned participants). Safety was assessed in all randomly assigned participants. The trial is registered with the ISRCTN registry (ISRCTN11853110); status completed. Findings: Between Sept 8, 2020, and Jan 14, 2022, 236 eligible participants were randomly assigned to active or sham Alpha-Stim AID (n=118 each). 156 (66%) participants were women, 77 (33%) were men, and three (1%) self-reported as other gender; 200 (85%) were White British or Irish; and the mean age was 38·0 years (SD 15·3; range 16–83). 102 (86%) participants in the active Alpha-Stim AID group and 98 (83%) in the sham group were followed up 16 weeks after randomisation. In the ITT population, mean change in GRID-HDRS-17 at 16 weeks was –5·9 (95% CI –7·1 to –4·8) in the active Alpha-Stim AID group and –6·5 (–7·7 to –5·4) in the sham group (mean change difference –0·6 [95% CI –1·0 to 2·2], p=0·46). Among the 236 participants, 17 adverse events were reported in 17 (7%) participants (nine [8%] participants in the active Alpha-Stim AID group; and eight [7%] participants in the sham group). One serious adverse event of suicidal ideation leading to hospitalisation was reported in the sham group, which was judged to be unrelated to the device. Interpretation: Active Alpha-Stim AID was safe and acceptable, but no more clinically effective than sham Alpha-Stim AID in major depression. Funding: National Institute for Health Research Applied Research Collaboration East Midlands and Electromedical Products International.

Citation

Morriss, R., Patel, S., Boutry, C., Patel, P., Guo, B., Briley, P. M., Butler, D., Craven, M., Duncan, A., Griffiths, C., Higton, F., McNaughton, R., Nixon, N., Prasad, V., Sayal, K., Smart, D., Zafar, A., & Kai, J. (2023). Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial. Lancet Psychiatry, 10(3), 172-183. https://doi.org/10.1016/S2215-0366%2823%2900007-X

• Journal Article Type: Article
• Acceptance Date: Jan 27, 2023
• Online Publication Date: Jan 29, 2023
• Publication Date: 2023-03
• Deposit Date: Feb 20, 2023
• Publicly Available Date: Feb 20, 2023
• Journal: Lancet Psychiatry
• Electronic ISSN: 2215-0366
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 10
• Issue: 3
• Pages: 172-183
• DOI: https://doi.org/10.1016/S2215-0366%2823%2900007-X
• Keywords: Biological Psychiatry; Psychiatry and Mental health
• Public URL: https://nottingham-repository.worktribe.com/output/16802599
• Publisher URL: https://www.sciencedirect.com/science/article/pii/S221503662300007X
• Additional Information: This article is maintained by: Elsevier; Article Title: Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial; Journal Title: The Lancet Psychiatry; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S2215-0366(23)00007-X; CrossRef DOI link to the associated document: https://doi.org/10.1016/S2215-0366(23)00028-7; Content Type: article; Copyright: © 2023 The Author(s). Published by Elsevier Ltd.